top of page
Cost-effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
Potnis K, Viswanathan G, Bona RD, Ito S, Kempton CL, Pandya A, Krumholz HK, Goshua G
American Journal of Hematology
September
2023
View Publication
​

​

Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP)
Butt A, Allen C, Purcell A, Ito S, Goshua G
Journal of Clinical Medicine
July
2023
View Publication
​

​

Distributional cost-effectiveness of equity-enhancing gene therapy in sickle cell disease in the United States.
Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A
Annals of Internal Medicine
May
2023
View Publication
First distributional cost-effectiveness analysis in the hematology-oncology arena. ASH Press Program Selection (1 of 2 in 2022). 2024 Outstanding Paper by a Young Investigator (SMDM).

First distributional cost-effectiveness analysis in the hematology-oncology arena. ASH Press Program Selection (1 of 2 in 2022). 2024 Outstanding Paper by a Young Investigator (SMDM).

Summiting thrombotic hazards in glioma
Goshua G and Lee AI
Blood
March
2023
View Publication
​

​

Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia
Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, Stahl M, Stein EM, Huntington SF, Zeidan AM
Leuk Lymphoma
February
2023
View Publication
​

​

Apixaban at apex? Aligning drug pricing with value in cancer-associated thrombosis
Ito S and Goshua G
Annals of Internal Medicine
January
2023
View Publication
​

​

Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A
American Journal of Hematology
January
2023
View Publication
​

​

Evidence-based minireview: should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?
Goshua G and Bendapudi PK
Hematology Am Soc Hematol Educ Program
December
2022
View Publication
​

​

Featured Publications (5)

All Selected Publications

Cost-effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
Potnis K, Viswanathan G, Bona RD, Ito S, Kempton CL, Pandya A, Krumholz HK, Goshua G
American Journal of Hematology
2023
September
RECOGNITIONS:

​

View Publicaton

​

PRACTICAL IMPACT:
Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP)
Butt A, Allen C, Purcell A, Ito S, Goshua G
Journal of Clinical Medicine
2023
July
RECOGNITIONS:

​

View Publicaton

​

PRACTICAL IMPACT:
Distributional cost-effectiveness of equity-enhancing gene therapy in sickle cell disease in the United States.
Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A
Annals of Internal Medicine
2023
May
RECOGNITIONS:

​

View Publicaton

First distributional cost-effectiveness analysis in the hematology-oncology arena. ASH Press Program Selection (1 of 2 in 2022). 2024 Outstanding Paper by a Young Investigator (SMDM).

PRACTICAL IMPACT:
Summiting thrombotic hazards in glioma
Goshua G and Lee AI
Blood
2023
March
RECOGNITIONS:

​

View Publicaton

​

PRACTICAL IMPACT:
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia
Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, Stahl M, Stein EM, Huntington SF, Zeidan AM
Leuk Lymphoma
2023
February
RECOGNITIONS:

​

View Publicaton

​

PRACTICAL IMPACT:
Apixaban at apex? Aligning drug pricing with value in cancer-associated thrombosis
Ito S and Goshua G
Annals of Internal Medicine
2023
January
RECOGNITIONS:

​

View Publicaton

​

PRACTICAL IMPACT:
Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A
American Journal of Hematology
2023
January
RECOGNITIONS:

​

View Publicaton

​

PRACTICAL IMPACT:
Evidence-based minireview: should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?
Goshua G and Bendapudi PK
Hematology Am Soc Hematol Educ Program
2022
December
RECOGNITIONS:

​

View Publicaton

​

PRACTICAL IMPACT:

Prophylactic weekly efanesoctocog alfa versus standard-care factor VIII in people living with severe hemophilia A: a cost-effectiveness analysis

Ito S, Potnis KC, Harvey JP, Sra M, Bewersdorf JP, Bona RD, Krumholz HM, Cuker A, Pandya A, Goshua G.
Annals of Internal Medicine
2025
June
FEATURED
RECOGNITIONS:
View Publication

Gap: First conventional and distributional cost-effectiveness analysis in the care of people living with hemophilia A (Yale-HSPH-Mayo-Penn collaboration). ASH Abstract Achievement Award (S. Ito).

PRACTICAL IMPACT:

Cost-effectiveness of Lynch syndrome screening in colorectal cancer: universal germline vs sequential screening

Ito S, Xicola RM, Sra M, Potnis KC, Singh V, Gershkovich P, Stites E, Gibson J, Krumholz HM, Llor X, Goshua G
Clinical Gastroenterology & Hepatology
2025
April
FEATURED
RECOGNITIONS:
View Publication

Gap: Real-world diagnostic attrition leads to missed diagnoses of inherited Lynch syndrome in probands with colorectal cancer (CRC) and their relatives. Health economic rationale for upfront germline tumor testing in probands to improve population health.

PRACTICAL IMPACT:

Cost-effectiveness of ferritin screening thresholds for iron deficiency in reproductive-age women

Wang D, Sra M, Glaeser-Khan S, Wang DY, Moshashaian-Asl R, Ito S, Cuker A, Goshua G
American Journal of Hematology
2025
April
FEATURED
RECOGNITIONS:
View Publication

Gap: First cost-effectiveness analysis of ferritin screening thresholds in the care of people living with iron deficiency (Yale-Mayo-Vermont-Penn collaboration). 2024 ASH Press Program Selection, 2025 Highlights of ASH, ASH Abstract Achievement Award (D. Wang).

PRACTICAL IMPACT:

Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria

Ito S*, Chetlapalli K*, Wang D, Potnis KC, Richmond R, Krumholz H, Lee AI, Cuker A, Goshua G.
Blood
2025
January
FEATURED
RECOGNITIONS:
View Publication

Gap: Proximal complement inhibition is cost-saving for patients with suboptimal response on C5 inhibitor therapy in the United States and can be cost-saving in international jurisdictions (Penn-Yale collaboration).

PRACTICAL IMPACT:

Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource

Ito S, Pandya A, Hauser RG, Krishnamurti L, Stites E, Tormey C, Krumholz HM, Hendrickson JE, Goshua G
American Journal of Hematology
2024
April
FEATURED
RECOGNITIONS:
View Publication

Gap: Supporting the mission of the 501(c)(3) Alloantibody Exchange www.alloantibody.org. 2022 ASH Press Program Selection.

PRACTICAL IMPACT:
Abstract Futuristic Background

Publications

bottom of page